Five isoforms of the muscarinic acetylcholine receptor (mAChR) have been identified by molecular cloning and designated m 1 -m 5 , of which four correspond to the functional subtypes M 1 , M 2 , M 3 , and M 4 in primary tissues. The presence of M 5 receptors in tissues remains uncertain. The present study was designed to explore the diversity and cellular distribution of various mAChR subtypes in human hearts. Competition binding of [N-methyl-3 H]-scopolamine methyl chloride with various mAChR antagonists yielded data consistent with the presence of multiple subtypes (M 1 /M 2 /M 3 /M 5 ) of mAChRs in both human atrial (HA) and ventricular (HV) tissues. Expression of mRNAs encoding all five subtypes was readily detected by reverse transcription-polymerase chain reaction in both HA and HV samples. Immunoblotting with subtype-specific antibodies confirmed the presence of M 1 , M 2 , M 3 , and M 5 , but not M 4 , proteins in membrane preparations from both HA and HV. The protein levels of M 1 and M 2 were comparable between HA and HV. Although the density of M 3 appeared ϳ10-fold higher in HV than HA, that of M 5 was ϳ5 times lower in HV than in HA. Positive immunostaining of single ventricular myocytes by M 1 , M 2 , M 3 , and M 5 antibodies, respectively, was consistently detected. Under confocal microscopy, M 5 showed characteristic localization to the intercalated discs, whereas other subtypes were more evenly distributed throughout the surface membrane. Our results provide the first molecular evidence for the presence of multiple subtypes of mAChR, including endogenous M 5 receptors, in human hearts and suggest that different subtypes have different tissue distributions and cellular localization.
Not until the 1990s were multiple subtypes (M 1 , M 2 , M 3 , and M 4 ) of mAChRs functionally defined in primary tissues with the development of pharmacological probes (Doods et al., 1987; Mitchelson, 1988; Goyal, 1989; Mutschler et al., 1989; Hulme et al., 1990; van Zwieten and Doods, 1995; Eglen and Watson, 1996) . cDNAs representing five different isoforms of mAChR subunits, m 1 through m 5 , have been cloned from a variety of mammals, including humans (Bonner et al., 1987; Peralta et al., 1987; Goyal, 1989; Brann et al., 1993) . M 1 -M 4 receptors seem to correspond to the cloned m 1 -m 4 isoforms, whereas the physiological counterpart of m 5 is yet to be established.
Muscarinic receptor stimulation by acetylcholine plays an important role in mediating parasympathetic control of cardiac functions such because heart rate, conduction, and contractility. In contrast to most peripheral tissues, the myocardium has generally been considered to possess a single mAChR subtype: M 2 receptors have long been believed to be the only functional mAChR subtype in the heart (Bonner et al., 1987; Peralta et al., 1987; Dörje et al., 1991; Pappano, 1991) . In fact, the heart is commonly used because a model illustrating the exclusive presence of M 2 receptors. However, the concept that the heart possesses a single M 2 subtype of mAChR is now being challenged. Many physiological responses to mAChR stimulation cannot be explained on the basis of a single M 2 subtype in the heart. Accumulating evidence suggests the existence of mAChR subtypes other than M 2 in cardiac tissues of chickens, rats, guinea pigs, rabbits, and dogs (Jaiswal et al., 1989; Akahane et al., 1990; Tietje and Nathanson, 1991; Ford, 1992; Yang et al., 1992; Gadbut and Galper, 1994; Kan et al., 1996; This work was supported in part by the Medical Research Council of Canada, the Heart and Stroke Foundation of Quebec, an Establishment Grant for young investigators from the Fonds de Recherche en Santé du Québec awarded to Dr. Wang Sun et al., 1996) , with large variations of subtype expression among species.
The cDNA of the m 5 muscarinic receptor was first cloned over a decade ago. In artificial expression systems, m 5 receptors have been shown to couple to multiple signaling mechanisms, including stimulation of phospholipase C-protein kinase C, phospholipase A 2 -arachidonic acid, and mitogenactivated protein kinase; inhibition of cAMP production; activation of nitric-oxide synthase; and intracellular calcium mobilization (Kohn et al., 1996; Reever et al., 1997; Kukkonen et al., 1998; Wotta et al., 1998) . The physiological significance of the m 5 subtype remains a mystery because of a lack of m 5 -selective ligands and a lack of evidence that primary tissues express the M 5 receptor. Only recently has the presence of native M 5 receptors in the brain been suggested by pharmacological approaches (Reever et al., 1997) .
We recently reported functional and molecular evidence for the presence of M 3 and M 4 receptors in canine (Shi et al., 1999a,b; Wang et al., 1999b) and M 3 receptors in guinea pig atrial myocytes Wang et al., 1999b) . We found these receptors to be functionally coupled to two novel and distinct K ϩ channels. Activation of M 3 receptors in guinea pig atrial preparations promotes membrane repolarization and slows sinus rate Wang et al., 1999b) . Whether the human heart possesses mAChRs other than M 2 remains unknown. To date, no systematic studies have examined mAChR subtypes in the human heart. We therefore examined the expression of various mAChR subtypes in human hearts by analyzing pharmacological properties (radioligand binding displacement), mRNA expression (RT-PCR), tissue protein concentrations (Western blot), and cellular protein distribution (immunostaining/confocal microscopy).
Materials and Methods
Membrane Protein Preparation. Specimens of human right atrial appendage (HA) were obtained from the hearts of four patients undergoing aortocoronary bypass surgery. The atria were from patients without heart failure, atrial arrhythmias, or electrocardiographic P-wave abnormalities and were grossly normal in appearance. Left ventricular tissues (HV) were dissected from the explanted hearts of four patients (aged 57-71) receiving heart transplantations. The procedure for obtaining the tissue was approved by the Ethics Committee of the Montreal Heart Institute.
The procedures for membrane protein preparation have been described previously (Shi et al., 1999a,b; Wang et al., 1999b) . The preparations were minced and washed with ice-cold phosphate-buffered saline (PBS) buffer. The tissues were then homogenized with a Polytron in 15 ml of ice-cold lysis buffer containing 5 mM Tris-HCl, 2 mM EDTA, pH 7.4, and a protease inhibitor cocktail consisting of 5 mg/ml phenylmethylsulfonyl fluoride, 10 mg/ml benzamidine, and 5 mg/ml soybean trypsin inhibitor. The homogenate was centrifuged at 500g for 15 min at 4°C. The pellets were then homogenized as before, spun again, and the supernatants pooled. The supernatants were centrifuged at 45,000g for 15 min and the pellets washed twice in the same buffer. The membrane fractions were resuspended in a buffer containing 75 mM Tris-HCl, pH 7.4, 12. 5 mM MgCl 2 , and 5 mM EDTA. The protein content was determined with Bio-Rad Protein Assay kit (Bio-Rad, Mississauga, ON, Canada) using bovine serum albumin as the standard. Chemicals were purchased from Sigma Chemical Co. (St. Louis, MO).
Membrane Receptor Binding Assay. Saturation binding assays were performed using eight concentrations of [N-methyl- 3 H]scopolamine methyl chloride ([ 3 H]NMS, 82 Ci/mmol) ranging from 2 to 2500 pM. Binding measurements were obtained in triplicate for each experiment with total of eight individual preparations (from four atria and four ventricles). Incubations at a volume of 1 ml (90 min at room temperature) were terminated by rapid filtration with Whatman GF/C filters (Xymotech, Montreal, PQ, Canada), and radioactivity was counted with an LS6500 Scintillation Counter (Beckman, Fullerton, CA). Nonspecific binding was defined as that measured in the presence of 1 M atropine. Specific binding (averaging ϳ90% of total binding) was determined by subtracting nonspecific from total binding (Shi et al., 1999a,b; Wang et al., 1999) .
Competition binding assays were carried out as follows (Shi et al., 1999a,b; Wang et al., 1999b) : Homogenates were incubated with 400 pM [
3 H]NMS and pirenzepine (0.3 nM-100 M), methoctramine (0.3 nM-100 mM), 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP, 0.1 nM-100 M), or tropicamide (1 nM-1 M), respectively. In addition, choline chloride (10 nM-10 mM) and tetramethylammonium (30 nM-1 mM), which have been shown to activate M 3 receptors in canine myocardium (Shi et al., 1999a,b) , were also studied in competition binding experiments. A fixed amount of membrane protein (100 g) was used for each binding study. Reagents for binding experiments were purchased from RBI/Sigma (Natick, MA).
RT-PCR. RNA was isolated as described previously (Wang et al., 1998 Shi et al., 1999; Yue et al., 1999) . RNA samples were isolated from adjacent tissues of the same hearts used for membrane protein extraction. Total RNA samples extracted from human atrial and ventricular tissues were incubated with DNase I (0.1 units/ml) at 37°C for 15 min, and this was followed by phenol/chloroform extraction to remove genomic DNA.
Reverse transcription was carried out in a 20-l reaction mixture containing 1ϫ reaction buffer [10 mM Tris-HCl, pH 8.3, 50 mM KCl, 2.5 mM MgCl 2 ], 1 mM dNTPs (Roche Molecular Biochemicals, Montreal, PQ, Canada), 3.2 mg of random primers p(dN) 6 (Roche Molecular Biochemicals), 5 mM dithiothreitol, 50 units of RNase inhibitor (Canadian Life Technologies, Burlington, ON, Canada), and 200 units of Moloney murine leukemia virus reverse transcriptase (Life Technologies). First-strand cDNA was synthesized at 42°C for 60 min, and remaining enzymes were heat-inactivated at 99°C for 5 min. First-strand cDNA (5 l) was used as a template for amplification in a 25-l reaction mixture. Reagents included in each reaction were 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 1 mM dNTPs, 0.5 M each gene-specific primer, and 2.5 units of Taq polymerase (Life Technologies). Reactions were hot-started at 94°C and continued for 3 min of initial melting. The cycling profiles were 30-s denaturing at 94°C, 30-s annealing at 52°C, and 40-s extension at 72°C, for 30 cycles, followed by a final extension step of 5 min at 72°C. The following primers were synthesized by Life Technologies: M 1 isoform, agactcctccaggccgctgc (sense) and ctcctttccacggggcttctg (antisense); M 2 isoform, aagaaggacaagaaggagcc (sense) and ctttggaatggcccagg (antisense); M 3 isoform, tggaacaacaatgatgctgc (sense) and ccttttccgcttagtgatctg (antisense); M 4 isoform, cccgaaggagaagaaagc (sense) and agtggtggcctctgtgg (antisense); and M 5 isoform, atcatgccctgccccttcc (sense) and gtagcttgctgttcccctgcc (antisense). All primers were designed to avoid significant secondary and complementary structures and to contain about 50 to 60% G-C content. The gene-specific primer pairs were designed based on cDNA sequences of human mAChRs (Peralta et al., 1987; Bonner et al., 1988) , and unique oligonucleotide sequences were chosen from cDNA regions with minimal homology among different mAChR isoforms. The specificity of primer pairs was verified by comparison with the entire GenBank database using BLAST and by amplification of a PCR product of the predicted size visible as a single discrete band with ethidium bromide staining on an agarose gel.
Western Blot Analysis. Membrane proteins (60 g) were fractionated by SDS-polyacrylamide gel electrophoresis (10% polyacrylamide gels) and transferred to nitrocellulose membranes (Immobilon-P, pore size 0.45 mm; Millipore Corporation, Bedford, MA) in a transfer buffer (25 mM Tris-base, 192 mM glycine, 20% methanol, and 0.01% SDS) Yue et al., 1999) . After transfer, the membrane was washed in Tris-buffered saline (Tris-HCl, NaCl, distilled H 2 O, pH 7.5) with 0.05% Tween 20 for 10 min and then incubated in a blocking buffer containing 5% nonfat dry milk in 0.1% Tris-buffer saline/Tween 20 (Tris-buffered ϩ 0.1% Tween 20) for 2 h, followed by overnight incubation at 4°C with the primary antibody. The M 1 , M 2 , M 3 , and M 5 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and the M 4 antibody from Chemicon International (Temecula, CA). The next day, the membrane was washed three times in 0.1% Tris-buffered saline/Tween 20 (10 min/ wash) and incubated for 2 h with the secondary antibody (avidinhorseradish peroxidase-conjugated goat anti-mouse IgG for M 4 and goat anti-rabbit IgG for other subtypes) in the blocking buffer. The membrane was then washed in the blocking buffer for 15 min. Bound antibodies were detected using chemiluminescent substrate (Western Blot Chemiluminescence Reagent Plus; PerkinElmer Life Science Products, Boston, MA). A rat brain protein sample (20 g) was used as a positive control for mAChRs and negative controls were performed by preincubating the antibodies with the respective peptides against which they are generated. The presence of a given subtype of mAChR was verified by the presence of a prominent band with molecular mass in the range of previous reports and by elimination of the band in preparations preincubated with the antigenic peptide. Potential cross-reaction of antibodies was excluded using purified M 1 , M 2 , M 3 , and M 5 receptors obtained from Santa Cruz Biotechnology. Coomassie staining was performed to verify the amount of protein inputs by incubate the membranes in Coomassie Brilliant Blue (prepared as a working solution in 50% methanol and 10% acetic acid solution) for 2 min and then washed to remove the background. Experiments were discarded if any visible differences between samples for comparison (HA versus HV) were found.
Immunocytochemistry. Human ventricular myocytes were isolated from the explanted hearts of three patients receiving heart transplantation, using methods described previously in detail (Li et al., 1995) . A segment of the left ventricular free wall containing a coronary artery was perfused via a Langendorff-type system with Ca 2ϩ -containing Tyrode's solution at 37°C until the effluent was clear of blood. The perfusate was then changed to Ca 2ϩ -free Tyrode's solution for 20 min at 12 ml/min, followed by perfusion with the same solution containing collagenase (110 U/ml CLS-II collagenase; Worthington Biochemical, Freehold, NJ) and 0.1% bovine serum albumin (Sigma Chemical Co., St. Louis, MO). The Tyrode's solution contained 136 mM NaCl, 5.4 mM KCl, 1 mM MgCl 2 , 0.33 mM NaH 2 PO 4 , 5 mM HEPES, 10 mM glucose, and 1 mM CaCl 2 ; pH was adjusted to 7.4 with NaOH.
The dispersed cells were washed twice with fresh PBS and plated on laminin (15 g/ml)-coated coverslips in the wells of culture dishes containing Dulbecco's modified Eagle's medium, supplemented with 10% heat-inactivated fetal bovine serum and antibiotics (10 mg/ml penicillin and 1 mg/ml streptomycin). Cells were incubated at 37°C for 1 h. The culture medium was then discarded and the cells were incubated with 1 ml of paraformaldehyde (1%, pH 7.4) for 30 min. After two washes with PBS, the cells were treated with Triton (1%) for 5 min to permeabilize cell membranes and then incubated overnight with 1% bovine serum albumin at 4°C. The following day, the cells were exposed to primary anti-mAChR antibodies for 2 h. After a PBS wash, the cells were incubated in secondary antibody for 1 h. Coverslips were then placed onto glass slides and sealed with mounting medium for confocal microscopy.
Data Analysis. Group data are expressed as the mean Ϯ standard error. Binding data were analyzed using curve-fitting functions in GraphPad Prism software (GraphPad Software, San Diego, CA). Linear regression was performed on the percentage of bound versus the ratio of bound over free ligand, and only data with a regression coefficient of Ն0.9 were used for analyses. The F test was used to compare fits for the competition binding data, and the best fit (onesite binding versus two-site binding) was determined by the probability value for the F test and by the change in the residual sum of squares for the two different fits. One-and two-site models were tested for all data sets, and the model yielding the least residual sum of squares was taken to describe the data. Densities of the immunoblot bands were quantified with the use of a Molecular Imager System (GS-505; Bio-Rad).
Results
Pharmacological Identification of Multiple Subtypes of mAChR in Human Hearts. [ 3 H]NMS binding to membrane homogenates from human atrial and ventricular tissues was saturable over the concentration range (2-2500 pM) examined. As illustrated in Fig. 1 , the experimental data were well fitted by a one-site binding model. Mean K d values were 220 Ϯ 20 pM for HA and 259 Ϯ 29 pM for HV, and the B max value was 280 Ϯ 40 fmol/mg protein for HA and 259 Ϯ 51 fmol/mg protein for HV (n ϭ 4/group). A Scatchard analysis of saturation binding data (Fig. 1A, inset) was linear, consistent with binding to a single class of receptor sites.
Competition binding studies were performed between [ 3 H]NMS (400 pM) and the following selective antagonists: pirenzepine (M 1 -selective) (Watson et al., 1983; van Zwieten and Doods, 1995) , methoctramine (M 2 -selective) (Michel and Whiting, 1988; van Zwieten and Doods, 1995) , 4-DAMP (M 3 -selective) (Barlow and Shepherd, 1986; Michel et al., 1989; Araujo et al., 1991; van Zwieten and Doods, 1995) , and tropicamide (M 4 -selective) (Lazareno et al., 1990; Lazareno and Birdsall, 1993) . The data from each curve gave the best fit to a two-site binding model (Fig. 1) . Table 1 provides pK i values, together with the percentage of total binding represented by (Doods et al., 1987; Mitchelson, 1988; Goyal, 1989; Mutschler et al., 1989; Hulme et al., 1990; Lazareno et al., 1990; Lazareno and Birdsall, 1993; van Zwieten and Doods, 1995; Eglen and Watson, 1996) suggests the presence of multiple mAChR subtypes (M 1 /M 2 /M 3 /M 5 ).
Expression of mRNAs Encoding Different mAChR Isoforms in Human Hearts. RT-PCR showed the presence of mRNA corresponding to all five mAChR isoforms (m 1 -m 5 ) in HA (Fig. 2A) To evaluate possible contamination of sample RNA by noncardiac tissue, we performed additional experiments investigating RT-PCR amplification of the neuronal acetylcholine ␤ 4 subunit (for neural contamination) and the maxi-K channel (Ca 2ϩ -activated K ϩ channel, for vascular contamination) (Wang et al., 1998 . Primers for ␤ 4 and maxi-K detected strong signals in RNA samples extracted from rat brain and rat vascular smooth muscle, respectively (Fig. 2B) . The absence of corresponding signals with cardiac RNA samples excludes significant neural and vascular tissue contamination of cardiac samples (Dixon and McKinnon, 1994; Wang et al., 1998) .
Immunoblotting of mAChR Proteins in Human Hearts. To clarify whether multiple mAChR subtypes also express at the protein level in human hearts, immunoblotting analysis was performed with fractionated HA and HV membrane proteins. Western blots with the anti-m 1 , m 2 , m 3 , or m 5 antibody revealed prominent protein bands at Ϸ100, 84, 113, and 80 kDa, respectively (Fig. 3A) . The bands were eliminated when the antibodies were preincubated with the respective peptides against which they were generated. Similar results were consistently obtained with all four preparations from different patients. The presence of proteins representing M 1 , M 2 , M 3 , and M 5 receptors were also consistently revealed in all three HV samples with band sizes identical to the respective subtypes found in the HA preparations. M 4 receptors were detected neither in HA nor in HV, even with increased quantities of both antibody and membrane preparation (up to 150 g/reaction). In contrast, the anti-m 4 antibody labeled a clear band representing M 4 receptors in the rat brain preparation, the positive control. For M 1-3 and M 5 receptors, the band sizes of the positive (rat brain) controls were in the same range as for the corresponding subtypes in the human heart.
A fixed amount of membrane protein (60 g) was used for each Western blot determination and the equal input of different protein samples was verified by Coomassie staining (No visible differences between HA and HV samples were found.). The densities of M 1 and M 2 receptors was equivalent in HA versus HV (1:1 HA:HV for M 1 and 1.2:1 for M 2 ). However, the expression of M 3 protein seemed higher in the HA, whereas that of M 5 was lower in HA, compared with HV, with HA:HV band density ratios of ϳ1:0.1 for M 3 and 0.2:1 for M 5 .
We considered the possibility that the bands identified in our experiments were due to cross-reaction with other mAChR subtypes. The subtype specificities of the antibodies have been tested and certified by the manufacturer (Santa Cruz Biotechnology). Nevertheless, to address the possibility further, we incubated pure preparations of expressed human M 1 , M 2 , M 3 , and M 5 receptors (RBI/Sigma) with each of the antibodies. No cross-reactivity was found for any of the five antibodies used in this study (Fig. 3B) ; each antibody identified a single band for the appropriate receptor, with a size similar to the corresponding band in human membrane proteins.
Immunostaining of mAChRs in Isolated Human Ventricular Myocytes. To investigate further the specific cellular localization of various mAChR subtypes in human heart cells, we performed immunocytochemistry with isolated human ventricular myocytes. M 5 receptor staining seemed to be largely restricted to the intercalated discs, whereas other receptor subtypes were evenly distributed along the surface membrane. M 3 receptors also demonstrated stronger staining on the intercalated discs relative to other regions of the plasma membrane. Nonspecific and subtype cross-reactivities were excluded by the elimination of staining after pretreatment of the antibodies with their respective antigenic peptides. Table 2 ). The high-affinity pK i (8.4) is consistent with the previously reported binding affinity of pirenzepine for M 1 receptors (Ϸ8.0) (Brann et al., 1993; van Zwieten and Doods, 1995; Eglen and Watson, 1996) and the fractional binding with this affinity is 28.7%, indicting a significant participation of M 1 receptors (Watson et al., 1983; van Zwieten and Doods, 1995) . On the other hand, the low-affinity binding (pK i ϭ 6.5) does not discriminate among subtypes. The high-affinity binding of methoctramine apparently confirms the existence of M 2 receptors (van Zwieten and Doods, 1995) , and the low-affinity binding (pK i ϭ 6.9) identifies but does not distinguish M 1 and M 4 subpopulations. Similarly, 4-DAMP binding also revealed two groups of mAChRs, with high-affinity binding (pK i ϭ 9.2) consistent with 4-DAMP affinity to M 3 and M 1 receptors (van Zwieten and Doods, 1995) and low-affinity binding (pK i ϭ (Lazareno et al., 1990; Lazareno and Birdsall, 1993) . The low-affinity binding of tropicamide (pK i ϭ 6.2) does not fit with previously reported binding to a specific subtype. Taken together, the results from our binding experiments point to the existence of M 1 , M 2 , and M 3 receptors in HA. Similar results were obtained from HV preparations. One important weakness of using receptor antagonists is a lack of perfect specificity toward different subtypes, although the compounds used in our study represent the best choices available. Therefore, caution must be taken when interpreting the binding data.
Messenger RNA sequences corresponding to M 1 , M 2 , M 3 , M 4 , and M 5 receptors were all detected in HA and HV tissues, in agreement with the results from the binding assays. These experiments provide a second line of evidence for the presence of multiple subtypes of mAChR in the human heart. More conclusive data were acquired from the Western blot analyses of membrane proteins, which revealed the presence of proteins representing M 1 , M 2 , M 3 , and M 5 receptors. Although M 4 was found to express at the mRNA level, the antibody targeting m 4 receptors failed to recognize M 4 proteins in human hearts, even when high concentrations of antibody and membrane proteins were used. This finding is unlikely to be due to a failure of the antibody used, because M 4 receptors were readily detected in rat brain preparations using the same antibody. Further studies are required to clarify whether the lack of M 4 protein expression is due to translational or post-translational mechanisms.
In addition, our immunoblotting data also reveal a heterogeneous distribution of mAChR subtypes between HA and HV. We found that, whereas the M 1 and M 2 subtypes were expressed at equivalent levels in HA and HV, M 3 and M 5 receptors were distributed heterogeneously. M 3 receptors were about 10-fold sparser in HV versus HA, and in sharp contrast, the density of M 5 receptors was about 5-fold higher in HV than in HA.
The total density of mAChRs in HA was not significantly different from that in HV, as suggested by the similar maximum capacity [ 3 H]NMS binding capacity in each ( Fig. 1 ; Table 2 ). We are unable at present to provide a quantitative comparison regarding the relative density of various subtypes of mAChR in HA or HV. Although the use of purified receptors or antigenic peptides can help to establish absolute quantities of various mAChR subtypes by generating standard curves on immunoblotting, adequate quantities of purified mAChRs are not currently available and the antigenic peptides available are too short to be detected.
Our control RT-PCR experiments (Fig. 3B ) make it unlikely that any of the mAChR signals that we detected was due to contamination by noncardiac sources. This notion is supported by the immunohistochemical data, which were in full agreement with the immunoblotting results. Antibodies directed against M 1 , M 2 , M 3 , and M 5 all produced clear positive staining of the plasma membrane, whereas the antibody to M 4 receptors failed to show any membrane staining.
Previous Studies Related to mAChR Subtypes in Hearts. Expression of multiple isoforms of mRNA encoding different subtypes of mAChRs (M 1 /M 2 /M 3 /M 4 ) in chick hearts has been reported by two groups (Tietje and Nathanson, 1991; Gadbut and Galper, 1994) . Sun et al. (1996) studied the antagonism of carbachol-induced chronotropy and inositol monophosphate accumulation in neonatal rat ventricular myocytes. They found that HHSiD, an M 3 -selective antagonist, blocked carbachol effects, whereas pirenzepine and AF-DX 116 (M 1 and M 2 antagonists) had no effect. They speculated that neonatal ventricular myocytes have a heterogeneous population of muscarinic receptors including M 2 and M 3 subtypes. Sharma et al. (1996 Sharma et al. ( , 1997 used single-cell PCR, subtype-specific antibodies, and the measurement of Ca 2ϩ transients to provide convincing molecular and functional evidence for the presence of M 1 receptors in rat ventricular myocytes. Ford et al. (1992) analyzed mAChR-mediated phosphoinositide hydrolysis in guinea pig atria and ventricles. The inhibition of the response to agonist by sev- eral antagonists, including HHSiD and p-F-HHSiD, generated an affinity profile dissimilar to the pure M 2 response, suggesting "a second population of muscarinic sites". In the isolated rabbit heart, acetylcholine increased prostaglandin synthesis and the effects were inhibited by low concentration of 4-DAMP (10 nM) (Jaiswal et al., 1989) . Although the investigators considered 4-DAMP an M 2 antagonist, the concentration they studied would probably block M 3 receptors, with minimal effects on M 2 receptors. The same group (Kan et al., 1996) has recently reevaluated the mAChR subtypes involved in prostacyclin synthesis and the authors now believe that acetylcholine can function via M 3 receptors in ventricular myocytes. In isolated blood-perfused dog atria, Akahane et al. (1990) compared the inhibitory potency of 4-DAMP, AF-DX 116, and pirenzepine for carbachol-induced negative chronotropic and inotropic responses. They found that the potency of 4-DAMP (an M 3 -preferring antagonist) was equal to that of atropine but greater than AF-DX 116 (an M 2 -preferring antagonist) and much greater than pirenzepine (an M 1 -selelctive inhibitor), suggesting a role of the M 3 subtype. Yang et al. (1992) performed a detailed pharmacological characterization of mAChR subtypes in membrane homogenates from dog left ventricular tissues. Their data favored the existence of M 2 and M 3 subtypes, and argued against the presence of M 1 receptors. Because of the imperfect selectivity of available pharmacological probes, none of these studies provided clear and unequivocal definitions of mAChR subtype distribution.
To our knowledge, the present work is the first systematic study of mAChR subtype expression in human hearts. Previous studies found only M 2 receptors in human hearts, with the inability to reveal other subtypes due presumably to the lack of subtype-selective antagonists. For example, Giraldo et al. (1988) suggested, based on binding data, that there is a single subtype of mAChR (M 2 ) in HA and HV. However, they used only two subtype-selective antagonists, pirenzepine (M 1 ) and AF-DX 116 (for M 2 ).
Potential Significance. One of the major innovations in the field of the cholinergic nervous system was the discovery of multiple subclasses of muscarinic receptors. Although many cellular responses to mAChR stimulation are mediated by the various subtypes of mAChR, M 2 receptors are commonly believed to be the only functional mAChR subtype in the heart (Dörje et al., 1991; Gadbut and Galper, 1994; Mizushima et al., 1987; Pappano, 1991; Tietje and Nathanson, 1991) . In many studies, the heart is often taken as a model for the exclusive presence of M 2 receptors. The present study, in conjunction with previous findings in other species, strongly suggests that multiple subtypes, and not just M 2 receptors, coexist in mammalian hearts. It seems that the one-receptor (M 2 ) concept needs to be revised and the potential participation of other mAChR subtypes in the cholinergic control of heart function must be considered. Prior work indicates that there are large species variations in terms of the subtypes of mAChR expressed in the hearts. M 1 and M 2 subtypes exist in rat hearts (Sharma et al., 1996) . M 2 , M 3 , and M 4 , but not M 1 and M 5 , receptors are present in dog hearts (H. Shi, H. Wang, and Z. Wang, unpublished data; Shi et al., 1999a) and there are M 2 , M 3 , and M 5 receptors in guinea pig hearts (H. Shi, H. Wang, and Z. Wang, unpublished data; Shi et al., 1999b) . Thus, extrapolation of data from animal species to humans must be done with caution.
Compared with other subtypes of mAChR, the M 5 receptor is probably the least known subtype in terms of its functional role in primary tissues, although its potential physiological function has been studied in heterologous expression systems (Kohn et al., 1996; Kukkonen et al., 1998; Reever et al., 1997) . The present study provides the first evidence for the presence of an endogenous M 5 receptor subtype in a peripheral non-neuronal tissue (Reever et al., 1997) . Although the function of the M 5 receptor is still unknown, our findings point to a potential functional role in the human heart.
We previously reported that stimulation of M 3 receptors by choline , pilocarpine , or tetramethylammonium (Shi et val., 1999a) in dog and guinea pig atrial myocytes activates a novel K ϩ current with both delayed and inward rectifier properties. Activation of M 3 receptors caused significant slowing of the heart rate and shortening of the action potential duration. Stimulation of M 4 receptors by 4-aminopyridine also induces a distinct K ϩ current in dog cells . Sharma et al. (1996) found that activation of M 1 receptors stimulates Ca 2ϩ transients in rat heart. The present study suggests potential relevance of the above-mentioned physiological observations to humans. Nevertheless, further direct experimentation is necessary to establish the function of M 1 , M 3 , and M 5 receptors in the human heart.
Our immunoblotting analysis indicated that M 3 and M 5 distributions are quantitatively different between HA and HV, with M 3 density higher in HA than in HV and M 5 higher in HV than in HA. In addition, immunostaining also revealed a characteristic localization of M 5 receptors to the intercalated discs. Other receptor subtypes were more evenly distributed throughout the surface membrane, although M 3 receptors also demonstrated a stronger staining on the intercalated discs relative to other regions of the plasma membrane. The data indicate that different subtypes of mAChR might have different patterns of cellular localization. Whether this heterogeneous distribution has functional implications awaits future studies.
In summary, we have obtained evidence with receptor binding, mRNA expression, and protein detection in support of the presence of multiple mAChR subtypes in human hearts. The tissue distribution (HV versus HA) and cellular localization vary among subtypes. These findings may open up opportunities for improved understanding of the subtype specificity of mAChR modulation of heart function and for the development of new drugs selectively targeting different subtypes of mAChRs.
